首页 › 基金 › Davern Capital Partners, LP › AVTX
Davern Capital Partners, LP 对 AVTX 的持仓历史
AVALO THERAPEUTICS INC · 医疗保健
Davern Capital Partners, LP 在 Q3 2026 的 13F 申报中披露持有 AVTX(AVALO THERAPEUTICS INC)564,441 股,市值约 US$8.7M,约占其申报组合的 1.68%,在其申报持仓中市值排名第 17 位。 Davern Capital Partners, LP 最近 2 个申报季度中有 2 个季度披露了 AVTX 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-12 · 来源: SEC EDGAR Form 13F-HR
Davern Capital Partners, LP 对 AVTX 的持仓演变
Davern Capital Partners, LP 于 Q2 2026 首次披露 AVTX 持仓:468,666 股(约 US$8.7M)。 在 2 次申报中,Davern Capital Partners, LP 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 564,441 股、市值约 US$8.7M,环比增持 95,775 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 468.67K | $8.66M | 新进 |
| Q3 2026 | 564.44K | $8.65M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AVTX 与 13F 数据
AVTX(AVALO THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 83 只申报持有 AVTX,申报仓位最大的包括:Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AVTX 的基金
- Deep Track Capital, LP 3.61M 股 · $66.71M · Q2 2026
- Caligan Partners LP 3.16M 股 · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M 股 · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M 股 · $53.59M · Q2 2026
- 法拉龙资本管理 2.50M 股 · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M 股 · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M 股 · $43.12M · Q2 2026
- BVF INC/IL 2.08M 股 · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M 股 · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M 股 · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M 股 · $30.11M · Q2 2026
- Logos Global Management LP 1.15M 股 · $21.25M · Q2 2026
更多关于 Davern Capital Partners, LP
常见问题
How long has Davern Capital Partners, LP held AVTX?
Davern Capital Partners, LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Davern Capital Partners, LP's current position in AVTX?
As of Q3 2026, Davern Capital Partners, LP holds 564.44K shares of AVTX (AVALO THERAPEUTICS INC), valued at $8.65M, representing 1.68% of its reported portfolio and ranking #17.
Has Davern Capital Partners, LP been buying or selling AVTX?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP increased its position in AVTX.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.